Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984965 | 0.91 | LTA4H (0.52) | METAP2METAP1LTA4HF10LMNA | |
| SCHEMBL19350607 | 0.89 | METAP2 (0.49) | METAP2METAP1LTA4HF10LMNA | |
| SCHEMBL12022090 | 0.89 | METAP2 (0.49) | METAP2METAP1LTA4HF10LMNA | |
| SCHEMBL7356680 | 0.88 | METAP2 (0.65) | METAP2METAP1LTA4HF10 | |
| Hydrochloric Acid SCHEMBL7354565 | 0.87 | METAP2 (0.64) | METAP2METAP1LTA4HF10 | |
| SCHEMBL22010038 | 0.86 | LTA4H (0.47) | METAP2METAP1LTA4HF10LMNA | |
| SCHEMBL3999277 | 0.83 | F10 (0.50) | METAP2METAP1LTA4HF10LMNA | |
| SCHEMBL22008905 | 0.82 | EPHX2 (0.56) | METAP2METAP1LMNAMEN1KMT2A | |
| SCHEMBL21929350 | 0.81 | METAP2 (0.47) | METAP2METAP1LTA4H | |
| SCHEMBL14984959 | 0.79 | METAP2 (0.51) | METAP2METAP1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | METAP2 1/4885METAP1 2/4885LTA4H 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.